UK regulators have approved a new daily weight loss pill named Foundayo. Produced by Eli Lilly, this medication is designed to manage both weight loss and type 2 diabetes. The pill functions as a GLP-1 receptor agonist, mimicking a natural hormone that regulates blood sugar, appetite, and digestion. It serves as an alternative to existing injectable treatments for those seeking to manage their condition.
While the drug has received regulatory approval, it is not currently available through the National Health Service. Patients will need to access the treatment via private prescriptions when it launches later this month. A spokesperson for the manufacturer confirmed the price will be lower than that of their Mounjaro injection, though specific costs are not yet finalized.
Foundayo offers a distinct clinical benefit by removing food or water intake restrictions. Unlike other oral weight loss medications that require specific timing regarding meals and beverages, this pill can be taken daily without strict dietary protocols. This addition to the market provides a different option for patients who require ongoing weight management support.
Clinical guidance notes that the treatment is intended to be used alongside a reduced-calorie diet and increased physical activity. Medical experts advise that while the drug produces clinically meaningful weight changes, it is associated with potential side effects common to GLP-1 medications. These include nausea, diarrhea, stomach cramps, and other gastrointestinal issues. Patients considering this new option should consult their healthcare providers to discuss their suitability for the treatment.